PubRank

Pia Wülfing

Author PubWeight™ 22.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005 1.56
2 Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005 1.52
3 An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 2007 1.35
4 Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009 1.27
5 Interobserver variability in the diagnosis of minimal and mild endometriosis. Eur J Obstet Gynecol Reprod Biol 2005 1.04
6 On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat 2007 1.02
7 Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry. Hum Pathol 2003 1.00
8 The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 2007 0.95
9 Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert Rev Anticancer Ther 2008 0.91
10 Metformin alters insulin signaling and viability of human granulosa cells. Fertil Steril 2005 0.91
11 Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest 2006 0.89
12 COX-2 overexpression in peritoneal lesions is correlated with nonmenstrual chronic pelvic pain. Eur J Obstet Gynecol Reprod Biol 2005 0.86
13 Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res 2006 0.83
14 Expression and prognostic relevance of endothelin-B receptor in vulvar cancer. Oncol Rep 2007 0.83
15 Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. Anticancer Res 2009 0.82
16 Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells. Int J Cancer 2010 0.82
17 Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol 2004 0.81
18 Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol 2007 0.81
19 Targeted therapies in breast cancer: established drugs and recent developments. Curr Clin Pharmacol 2008 0.81
20 ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. Breast Cancer Res Treat 2009 0.81
21 Impact of AdipoR1 expression on breast cancer development. Gynecol Oncol 2010 0.80
22 Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival. Eur Urol 2005 0.78
23 Egfr amplification specific gene expression in phyllodes tumours of the breast. Cell Oncol 2007 0.77
24 Expression of endothelin-1 and endothelin-A and -B receptors in invasive bladder cancer. Oncol Rep 2005 0.75
25 Detection of nonpigmented endometriotic lesions with 5-aminolevulinic acid-induced fluorescence. J Am Assoc Gynecol Laparosc 2004 0.75
26 Improvements in the analysis strategy make single nucleotide polymorphism analysis a powerful tool in the detection and characterization of amplified chromosomal regions in human tumors. Pathobiology 2006 0.75